Digest Network Come funziona
Network
/
Società
H.
Non verificato

H. Lundbeck A/S

Di cosa scriviamo

AgricolturaEcologia/Salute ambientaleFitnessMedicina - VarieSalute

20 comunicati stampa

Guarda tutti i comunicati
23/07/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
20/07/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
24/06/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
24/06/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
15/06/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
10/06/2026
Salute
Fitness
Fiere
Eventi
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
04/06/2026
Salute
Fitness
Fiere
Eventi
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
26/05/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
18/05/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0
19/04/2026
Salute
Fitness
Cronaca Rosa / Gossip
Cronaca Bianca
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
Fonte
H. Lundbeck A/S
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0